Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
21 January, 2019 06:36 IST
Lupin receives USFDA approval for pregnancy prevention tablets
Source: IRIS | 14 Jun, 2018, 03.47PM
Comments  |  Post Comment

Pharma major Lupin announced that it has received final approval fonts Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and LevomefolateCalcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Bayer HealthCare Pharmaceutical Inc.'s (Bayer) Beyaz®Tablets.

Lupin's Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, are the generic equivalent of Bayer's Beyaz® Tablets. It is indicated for use by women to:

> prevent pregnancy;

> treat symptoms of premenstrual dysphoric disorder (PMDD) for women who choose to use an oral contraceptive for contraception;

> treat moderate acne for women at least 14 years old, only if the patient desires an oral contraceptive for birth control; and

> raise folate levels in women who choose to use an oral contraceptive for contraception

Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg had annual sales of approximately U5D 82.2 million in the US (IOWA MATApril 2018).

Shares of the company gained Rs 47.7, or 5.58%, to trade at Rs 902.00. The total volume of shares traded was 391,151 at the BSE (3.30 p.m., Thursday).





Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Ratnamani Metals & Tubes receives order worth Rs 2 bn - 18-Jan-2019 15:59
Aurobindo Pharma to acquire portfolio of oncology injectables products - 18-Jan-2019 13:47
Reliance Ind Q3 earnings up 8.8%; GRM's at USD 8.8/bbl - 18-Jan-2019 13:08
Announcement under Regulation 30 (LODR)-Change in Directorate - 18-Jan-2019 11:14
Zydus receives final approval for Acetazolamide ER capsules - 17-Jan-2019 13:27
OnMobile Global renews its contract with Telefonica Moviles Espana, SAU (Telefonica) - 17-Jan-2019 10:14
Suven Life Sciences secures 2 overseas product patents - 16-Jan-2019 13:45
Texmaco Rail & Engineering receives orders worth Rs 2.62 bn - 16-Jan-2019 12:59
Dr Reddy's announces completion of USFDA audit of formulation facility - 16-Jan-2019 10:15
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer